Modality
ERT
MOA
BCMA ADC
Target
FXIa
Pathway
Notch
SCLCCeliacRA
Development Pipeline
Preclinical
~Jan 2011
→ ~Apr 2012
Phase 1
~Jul 2012
→ ~Oct 2013
Phase 2
~Jan 2014
→ ~Apr 2015
Phase 3
~Jul 2015
→ ~Oct 2016
NDA/BLA
Jan 2017
→ Jun 2031
NDA/BLACurrent
NCT04837024
1,342 pts·RA
2017-01→2031-06·Recruiting
1,342 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-245.2y awayPh3 Readout· RA
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2031-06-24 · 5.2y away
RA
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04837024 | NDA/BLA | RA | Recruiting | 1342 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |